Notify me when Theleme Partners LLP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | 10 | $1.56B | +$104M | -$172M | -$67.9M | META, WFC, MRNA, TRU, UBER | 13F-HR | 11/13/2025, 01:28 PM |
| Q2 2025 | 10 | $1.65B | +$383M | -$145M | +$238M | MRNA, WFC, META, TRU, FLUT | 13F-HR | 8/13/2025, 05:43 PM |
| Q1 2025 | 12 | $1.27B | +$130M | -$202M | -$71.3M | MRNA, AMZN, WFC, TRU, EFX | 13F-HR | 5/14/2025, 06:08 PM |
| Q4 2024 | 11 | $1.49B | +$617M | -$598M | +$19M | MRNA, BAC, WFC, AMZN, EFX | 13F-HR | 2/13/2025, 06:15 PM |
| Q3 2024 | 10 | $1.7B | +$303M | -$316M | -$12.8M | MRNA, SCHW, TRU, EFX, HRI | 13F-HR | 11/14/2024, 12:52 PM |
| Q2 2024 | 8 | $2.01B | +$232M | -$120M | +$112M | MRNA, SCHW, WFC, TRU, HRI | 13F-HR | 8/13/2024, 05:45 PM |
| Q1 2024 | 7 | $1.82B | +$124M | -$349M | -$225M | MRNA, SCHW, WFC, HRI, TRU | 13F-HR | 5/14/2024, 10:34 AM |
| Q4 2023 | 9 | $1.9B | +$138M | -$453M | -$315M | MRNA, SCHW, WFC, HRI, TSM | 13F-HR | 2/13/2024, 09:55 AM |
| Q3 2023 | 10 | $1.99B | +$188M | -$205M | -$17.1M | MRNA, SCHW, WFC, QCOM, URI | 13F-HR | 11/13/2023, 06:01 PM |
| Q2 2023 | 9 | $2.21B | +$280M | -$250M | +$29.9M | MRNA, WFC, SCHW, URI, AA | 13F-HR | 8/11/2023, 06:21 PM |
| Q1 2023 | 11 | $2.33B | +$338M | -$386M | -$47.8M | MRNA, WFC, SCHW, AA, QCOM | 13F-HR | 5/12/2023, 05:35 PM |
| Q4 2022 | 10 | $2.6B | +$237M | -$198M | +$38.4M | MRNA, WFC, SCHW, AA, URI | 13F-HR | 2/10/2023, 04:14 PM |
| Q3 2022 | 10 | $2.05B | +$58.8M | -$253M | -$194M | MRNA, WFC, SCHW, META, AA | 13F-HR | 11/14/2022, 12:12 PM |
| Q2 2022 | 12 | $2.5B | +$167M | -$95.7M | +$71.7M | MRNA, WFC, LRCX, META, AA | 13F-HR | 8/12/2022, 11:14 AM |
| Q1 2022 | 11 | $3.13B | +$623M | -$298M | +$324M | MRNA, WFC, AA, LRCX, META | 13F-HR | 5/13/2022, 01:37 PM |
| Q4 2021 | 9 | $3.25B | +$704M | -$574M | +$131M | MRNA, WFC, AA, META, MU | Restatement | 5/26/2022, 12:11 PM |
| Q3 2021 | 7 | $3.5B | +$368M | -$1.15B | -$780M | MRNA, WFC, META, AA, TMUS | Restatement | 5/26/2022, 12:04 PM |
| Q2 2021 | 9 | $3.42B | +$203M | -$621M | -$418M | MRNA, WFC, TMUS, ADI, MU | 13F-HR | 8/13/2021, 02:26 PM |
| Q1 2021 | 12 | $2.99B | +$438M | -$730M | -$293M | MRNA, WFC, TMUS, AZO, MU | 13F-HR | 5/13/2021, 12:36 PM |
| Q4 2020 | 15 | $2.87B | +$1.04B | -$731M | +$310M | WFC, MRNA, TMUS, CARR, MU | 13F-HR | 2/12/2021, 04:04 PM |
| Q3 2020 | 15 | $2.04B | +$275M | -$347M | -$72.2M | MRNA, WFC, URI, VMC, BKNG | 13F-HR | 11/13/2020, 02:48 PM |
| Q2 2020 | 14 | $1.97B | +$542M | -$238M | +$304M | MRNA, WFC, URI, VMC, BKNG | 13F-HR | 8/13/2020, 07:34 PM |
| Q1 2020 | 13 | $1.22B | +$449M | -$577M | -$128M | WFC, MRNA, URI, BA, MU | 13F-HR | 5/14/2020, 05:39 PM |
| Q4 2019 | 7 | $1.78B | +$78.6M | -$406M | -$327M | WFC, BAC, URI, AXP, MRNA | 13F-HR | 2/13/2020, 10:03 AM |
| Q3 2019 | 10 | $1.89B | +$239M | -$114M | +$125M | WFC, BAC, URI, SCHW, AXP | 13F-HR | 11/13/2019, 02:54 PM |
| Q2 2019 | 9 | $1.68B | +$357M | -$354M | +$3.31M | WFC, BAC, SCHW, URI, KLAC | 13F-HR | 8/13/2019, 08:38 PM |
| Q1 2019 | 8 | $1.67B | +$271M | -$355M | -$84M | BAC, WFC, SCHW, UTX, AXP | 13F-HR | 5/15/2019, 02:19 PM |
| Q4 2018 | 9 | $1.64B | +$154M | -$59.8M | +$93.7M | WFC, SCHW, BAC, UTX, SPGI | 13F-HR | 2/13/2019, 06:12 PM |
| Q3 2018 | 7 | $1.83B | +$68.1M | -$159M | -$91M | WFC, SCHW, BAC, UTX, SPGI | 13F-HR | 11/13/2018, 04:29 PM |
| Q2 2018 | 8 | $1.93B | +$244M | -$272M | -$28.8M | SCHW, WFC, BAC, BACWSA, UTX | 13F-HR | 8/13/2018, 03:52 PM |
| Q1 2018 | 7 | $1.99B | +$158M | -$88.4M | +$69.9M | SCHW, WFC, BAC, BACWSA, SPGI | 13F-HR | 5/14/2018, 01:45 PM |
| Q4 2017 | 6 | $1.96B | +$129M | -$267M | -$138M | SCHW, WFC, BAC, BACWSA, SPGI | 13F-HR | 2/14/2018, 10:32 AM |
| Q3 2017 | 7 | $1.81B | +$77.1M | -$89.9M | -$12.8M | BAC, SCHW, WFC, BACWSA, SPGI | 13F-HR | 11/13/2017, 10:50 AM |
| Q2 2017 | 6 | $1.77B | +$13.3M | -$184M | -$171M | SCHW, BAC, WFC, BACWSA, SPGI | 13F-HR | 8/11/2017, 01:24 PM |
| Q1 2017 | 7 | $1.87B | +$104M | -$115M | -$10.5M | SCHW, BAC, WFC, SPGI, BACWSA | 13F-HR | 5/12/2017, 12:59 PM |
| Q4 2016 | 7 | $1.77B | +$79.4M | -$54.8M | +$24.7M | SCHW, BAC, WFC, SPGI, BACWSA | 13F-HR | 2/13/2017, 10:22 AM |
| Q3 2016 | 6 | $1.39B | +$162M | -$245M | -$82.2M | SCHW, BAC, WFC, SPGI, CHTR | 13F-HR | 11/14/2016, 02:23 PM |
| Q2 2016 | 7 | $1.33B | +$203M | -$344M | -$141M | WFC, SCHW, BAC, VMC, SPGI | 13F-HR | 8/12/2016, 10:06 AM |
| Q1 2016 | 8 | $1.49B | +$216M | -$106M | +$111M | WFC, SCHW, BAC, VMC, MHFI | 13F-HR | 5/13/2016, 10:17 AM |
| Q4 2015 | 8 | $1.52B | +$57.2M | -$66.1M | -$8.98M | WFC, SCHW, BAC, VMC, MHFI | 13F-HR | 2/12/2016, 11:02 AM |
| Q3 2015 | 8 | $1.41B | +$106M | -$127M | -$21.2M | WFC, SCHW, BAC, VMC, MHFI | 13F-HR | 11/13/2015, 01:23 PM |
| Q2 2015 | 9 | $1.57B | +$179M | -$173M | +$5.61M | WFC, SCHW, BAC, MHFI, VMC | 13F-HR | 8/13/2015, 11:31 AM |
| Q1 2015 | 9 | $1.49B | +$165M | -$332M | -$167M | WFC, SCHW, BAC, MHFI, MSFT | 13F-HR | 5/14/2015, 09:56 AM |
| Q4 2014 | 8 | $1.67B | +$221M | -$131M | +$90.6M | WFC, SCHW, BAC, MHK, MHFI | 13F-HR | 2/13/2015, 02:56 PM |
| Q3 2014 | 8 | $1.51B | +$91M | -$128M | -$37M | WFC, SCHW, BAC, MHFI, MHK | 13F-HR | 11/13/2014, 10:34 AM |
| Q2 2014 | 10 | $1.5B | +$142M | -$207M | -$65.7M | WFC, SCHW, BAC, MHFI, LOW | 13F-HR | 8/13/2014, 01:18 PM |
| Q1 2014 | 12 | $1.53B | +$143M | -$349M | -$206M | WFC, SCHW, BAC, MHFI, LOW | 13F-HR | 5/14/2014, 10:13 AM |
| Q4 2013 | 14 | $1.69B | $0 | $0 | WFC, SCHW, AXP, BAC, MHFI | 13F-HR | 2/13/2014, 09:21 AM |